Eli Lilly says Foundayo met primary endpoint at week 52 in ATTAIN-OSA trial

Eli Lilly announced that Foundayo met its primary endpoint at week 52 in the ATTAIN-OSA trial, reducing the apnea-hypopnea index and lowering sleep apnea-specific hypoxic burden by up to an average of 55.9%.

Detected & updated continuously · Source: Nebula